This Week in Psychedelics - 11.19.21

Cannabis

• U.S. Republicans move to decriminalize marijuana at federal level (Reuters)

• Germany Set To Legalize Marijuana Nationwide After Major Parties Reach Agreement (Marijuana Moment)

• Brazil is on The Brink of Medical Cannabis Change (High Times)

• Is This The First Real Case Of Fentanyl-Tainted Marijuana In The U.S.? (Forbes)

• Indiana Democratic Party Backs Marijuana Legalization And Pledges 2022 Reform Push (Marijuana Moment)

• New York Senator Files Bill To Extend Marijuana Equity Benefits To Transgender And Non-Binary People (Marijuana Moment)

• Straws Lined with THC Could Transform Edibles Industry (High Times)

• Bipartisan Wisconsin Lawmakers Unveil Marijuana Decriminalization Bill (Marijuana Moment)

• New study shows no increase in car crash injuries after marijuana legalized (Vancouver Sun)

• Canadian Groups Gives Free Weed And Edibles To Fight Opioid Abuse (High Times)

• Marijuana Legalization Attitudes Vary Significantly Within Partisan Coalitions, Pew Survey Shows (Marijuana Moment)

• Creating a better cannabis cultivation facility while strengthening relationships with third-party testing labs (Marijuana Business Daily)

• Sturdy Hemp Structures Could be the Future Eco-Building (High Times)

• Using cannabis in pregnancy linked to aggression and anxiety in children, a study suggests (CNN)

• Study: Scarification of cannabis seeds, certain disinfectants boost germination rates (Marijuana Business Daily)

LSD

• MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures (Psilocybin Alpha)

• Up, Up and Away: The Trippy Tales Behind ‘Flying Over Sunset’ (The New York Times)

• Is LSD Safe - Latest Research Findings (Drug Science)

• The LSD Comedown: Navigating the After Effects of Acid (DoubleBlind)

Magic Mushrooms

• Bill on magic mushrooms aims to make Pa. a national leader in psychedelic research (The Philadelphia Inquirer)

• NYC Subways Ban Marijuana And Psychedelic Mushroom Ads (Marijuana Moment)

• Magic Mushrooms, A Love Story (The New Yorker)

• PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch (Psilocybin Alpha)

• Tryp Therapeutics Provides Update on Clinical Hold for Phase 2a Study for Eating Disorders (Yahoo!)

• TheraPsil and Imperial College London, McGill University Partner on Psilocybin Study (Truffle Report)

• Red Light Holland Psilocybin Truffles, Sold in The Netherlands, Complete First Evaluation Under a Health Canada Approved cGMP Laboratory (Psilocybin Alpha)

• Another Life: Foraging for mushrooms and natural psychedelics (The Irish Times)

MDMA

• World's 'Strongest-Ever' Ecstasy Pill Found in English Nightclub (VICE)

DMT

• Algernon Announces Positive Feedback on its Planned Phase 1/2a DMT Human Stroke Study (Yahoo!)

• Discussions With FDA Provide Guidance for Phase IIb Clinical Trial Design for DMT-Assisted Therapy for Major Depressive Disorder (Psilocybin Alpha)

Ayahuasca

• Is This Phoenix Pastor a Spiritual Shaman or an Ayahuasca Kingpin — or Both? (Phoenix New Times)

• Ron White’s strange ayahuasca experience, as described on JRE. (Ceng News)

5-MeO-DMT

• Mike Tyson ‘died’ while tripping on psychedelic toad venom (New York Post)

• Biomind Labs Completes Development of a Thermosensitive Nasal Gel Pharmaceutical Dosage Form (Business Wire)

Novel Psychoactive Substances

• New Psychedelic Molecules: What’s in Development? (Truffle Report)

• New Psychedelic Molecules Part II: Key Industry Players (Truffle Report)

• Researchers train computers to predict the next designer drugs (ScienceDaily)

• BetterLife Pharma says pharmacology data on second-generation LSD derivative confirms its projected non-hallucinogenic property (Proactive Investors)

Ketamine

• Michael J. Fox Foundation Grant Will Fund First Clinical Trial of Ketamine to Treat Depression in People with Parkinson’s Disease (Yale School of Medicine)

• Warning of ‘wild west’ in depression treatment as UK clinics offer ketamine (The Guardian)

• Bexson Biomedical Announces Expansion to Treat Major Depression with Wearable Ketamine Formulation (PR Newswire)

• Silo Pharma and Strategic Partner Zylo Therapeutics Begin Development Process for Novel Ketamine Loaded Z-Pods (Psilocybin Alpha)

DXM

• Teenagers are ‘robotripping’ in the pursuit of cheap highs, again (Screenshot Media!)

Miscellaneous

• Jon Hopkins’s Psychedelic Journey to a New Way of Creating Music (The New York Times)

• "Aharon said it was healing:" How psychedelic therapy was undermined by abuse (Inverse)

• Psychedelics Use Associated With 55 Percent Decrease In Daily Opioid Consumption, Study Finds (Marijuana Moment)

• Horizons Conference Reconvenes in NYC to Connect Psychedelic Communities (Lucid News)

• New Non-Profit Supports Groundbreaking HPPD or ‘Acid Flashback’ Research (Truffle Report)

• Inside The Race To Create A Two-Hour Psychedelic Therapy Experience (Forbes)

• Psychedelics Help Heal Childhood Trauma, Study Finds (Benzinga)

• Psychedelic Bypassing: When Avoidance is Mistaken for Healing (Psychedelics Today)

• Canadian Biotech Known For Psilocybin And Cannabinoid-Based Medicines In FDA Phase 3 Trial For Bucillamine-Based Oral Covid Treatment (Forbes)

• Three Decades of Drug Policy Reform Work (Open Society Foundations)

• A Close Reading of the QAnon Shaman’s Conspiracy Manifesto (Lit Hub)

• Naropa University Announces Psychedelic-Assisted Therapies Certificate (Tricycle)

• A New Psychedelic Organization is Merging Shamanism and Science (Lucid News)

• The Serotonin 5-HT2A Receptor: From Mice to Humans (Psychedelic Science Review)

• Animals That Eat Psychedelics and Enjoy the Trip (Psychedelic Spotlight)

• CaaMTech Teams Up With University of Wyoming to Study Psychedelics as Treatments for Addiction (Psilocybin Alpha)

• MYND Diagnostics Commences Clinical Research on Alzheimer’s Disease (Psilocybin Alpha)

• Letting people test their drugs will reduce the number of needless deaths (The Independent)

• The History of Psychedelics: An ancient tradition (Canex)

• MYND Diagnostics Commences Clinical Research on Multiple Sclerosis Biomarker Test (Psilocybin Alpha)

Think Wilder is reader-supported. If you enjoyed this week’s update, please consider helping out by becoming a patron, making a one-time donation, or sharing this post with a friend. Thank you for your support.

Disclaimer: "This Week in Psychedelics" does not censor or analyze the news links presented here. The purpose of this column is solely to catalog how psychedelics are presented by the mass media, which includes everything from the latest scientific research to misinformation.

This Week in Psychedelics - 11.12.21

Cannabis

• Top Mexican Senator Says There’s Agreement To Prioritize Marijuana Legalization Legislation This Session (Marijuana Moment)

• Germany’s Next Coalition Nears Deal on Legalizing Cannabis (Bloomberg)

• Texas judge allows legal sale of delta-8 products—for now (Leafly)

• New York adopts final rules banning delta-8 THC, smokable hemp (HempToday)

• Another Poll Shows Majority Support For Marijuana Legalization, Including Most Republicans (Marijuana Moment)

• Herbal Supplement Giant To Enter THC, Psychedelics Industries, Seeking To Become First Household Brand To Do So (Forbes)

• This MMA fighter is taking on cannabis stigma in sports (Leafly)

• What Happens When You Mix Cannabis With Psychedelics? (IFLScience)

• Marijuana Legalization In Canada Did Not Result In Increased Traffic Injuries, Study Finds (Marijuana Moment)

• Medical Cannabis for Epilepsy - Research Summary and Recommendations (Drug Science)

• Medical Cannabis Sales Finally Set to Begin in West Virginia (NORML)

• South Dakota Marijuana Activists Delay Legalization Signature Delivery After Missing Initial Deadline (Marijuana Moment)

• Cannabis requires more water than commodity crops, researchers say (Marijuana Business Times)

LSD

• Sweden Experimenting With Rats on LSD to Cure Depression, Addiction (Sputnik News)

• How Likely Are Bad Trips and Flashbacks from LSD? (Psychedelic Science Review)

• Blackhawk Growth's MindBio Therapeutics Completes Safety Milestone in its Phase 1 Clinical Trials (Yahoo!)

Magic Mushrooms

• Largest psychedelic therapy trial to date delivers mixed results (New Atlas)

• Nonprofit Hosts Canada’s First Legal Psilocybin Group Therapy (Truffle Report)

• Australian Therapists to Be Given Psilocybin to Better Understand Their Patients (VICE)

• Denver City Council Considers Expanding Psilocybin Decriminalization (Marijuana Moment)

• Psilocybin therapy boosts cognitive and neural flexibility in depressed patients, study finds (PsyPost)

• A Look at Connecticut’s Psilocybin Study Workgroup (Truffle Report)

MDMA

• Doctor takes bid to treat patient with MDMA to court, in first case of its kind in Australia (Australian Broadcasting Corporation)

• The Story Behind the 'First Ever Ecstasy Song' (VICE)

• Expert: MDMA Is Very Likely to Be FDA-Approved for PTSD by the End of 2023 (Pharmacy Times)

• Veteran Who Cured PTSD with MDMA-Assisted Therapy Wows NBC ‘Today’ Show Anchors (Psychedelic Spotlight)

• Numinus to Host Extension of MAPS-Sponsored MDMA-Assisted Therapy for PTSD Trials (PR Newswire)

Ayahuasca

• A cancer doctor said doing ayahuasca saved his marriage and relationship with his 2 young children (Yahoo!)

Novel Psychoactive Substances

• Pre-Clinical Data Shows Cybin’s Novel Analog Could Have Advantages Over Psilocybin (Forbes)

• Forgotten Psychedelics: What Is 2C-B? (Psychedelic Spotlight)

Ketamine

• Baby Girl Died From 'Acute Ketamine Intoxication,' and Prosecutors Charge Washington Father With Murder (The Daily Chronicle)

• Single Infusion of Ketamine Rapidly Reduces Suicidal Thoughts (Medscape)

• Warning of ‘wild west’ in depression treatment as UK clinics offer ketamine (The Guardian)

• Psychedelics Wellness Scores Big Win With New Mainstream Deal (Forbes)

Miscellaneous

• DEA Boosts Psilocybin, MDMA And DMT Production Levels Again In Final Quotas For 2021 (Marijuana Moment)

• New Website Details Abuse Allegations Against German Psychedelic Practitioners (Psymposia)

• Big Tech's Psychedelics Grift (WIRED)

• Prosecutors seek 4+ years in prison for 'QAnon Shaman' in attempt to set example (CNN)

• Will the magic of psychedelics transform psychiatry? (The Guardian)

• Veterans Have Become Unlikely Lobbyists in Push to Legalize Psychedelic Drugs (The New York Times)

• Psychedelics Could Become Extractive Capitalism—Unless We Hold Stakeholders Accountable (DoubleBlind)

• Tim Ferriss Funds Fellowships for Journalists Reporting On Psychedelics (Lucid News)

• 6 Ways the Psychedelic Space Can Divest From Whiteness (DoubleBlind)

• Is Microdosing a Placebo? Here’s what our Head of Research Says (The Third Wave)

• Countries not adequately addressing illegal drug use: Experts (The Straits Times)

• Startup offers psychedelic-assisted mental wellness therapies (Axios)

• The Masters of Bad Trips (Psymposia)

• Monash University announces establishment of the Neuromedicines Discovery Centre to Focus on Psychedelic-Assisted Therapies for the Treatment of Key Classes of Mental Illness (Mind Medicine Australia)

• Psychedelic Company Lists on NASDAQ as ‘DRUG’ (High Times)

Think Wilder is reader-supported. If you enjoyed this week’s update, please consider helping out by becoming a patron, making a one-time donation, or sharing this post with a friend. Thank you for your support.

Disclaimer: "This Week in Psychedelics" does not censor or analyze the news links presented here. The purpose of this column is solely to catalog how psychedelics are presented by the mass media, which includes everything from the latest scientific research to misinformation.

This Week in Psychedelics - 11.5.21

Cannabis

• Voters In Seven Ohio Cities Approve Marijuana Decriminalization Ballot Measures, With Seven Others Defeated (Marijuana Moment)

• 3 Years Since the UK Legalised Medical Cannabis, and Only 3 NHS Prescriptions (Drug Science)

• New Congressional Report Provides Pathway for How the Biden Administration Can Deschedule Marijuana and Issue Blanket Pardons to Past Offenders (NORML)

• Pakistan Vows Cannabis Reform by End of Year (High Times)

• Strong Majority Of Americans Continues To Support Marijuana Legalization At Record High Level, New Gallup Poll Finds (Marijuana Moment)

• California legalized weed five years ago. Why is the illicit market still thriving? (The Guardian)

• Philadelphia Voters Approve Marijuana Referendum Calling For Statewide Legalization (Marijuana Moment)

• Virginia: Election Outcomes Likely to Influence Marijuana Legalization Launch (NORML)

• DEA Emboldens Delta-8 Hemp Businesses By Signaling That The Cannabinoid Is Federally Legal (Marijuana Moment)

• Marijuana Legalization Is Not Associated With Increased Mental Illness Or Suicide, New Study Finds, Despite Opposition Claims (Marijuana Moment)

• Mississippi Governor Stalls Medical Cannabis Bill (High Times)

• Legalizing Marijuana Reduces ‘Race-Based Arrests,’ American Medical Association Study Finds (Marijuana Moment)

• Cannabis growers eye drought-resistant strains to cope with water shortage (Marijuana Business Daily)

• Arkansas Activists File New Marijuana Legalization Initiative For 2022 Ballot (Marijuana Moment)

• Medical marijuana could ease anxiety, depressive symptoms, study shows (Marijuana Business Daily)

• Concentrates and vape products maintain dominance among heavy cannabis users (Marijuana Business Daily)

• Government-Grown Marijuana Is Genetically Closer To Hemp Than Cannabis Sold In Dispensaries, Another Study Finds (Marijuana Moment)

• Edibles and beverages are popular choices with new cannabis users (Marijuana Business Daily)

• Army Recruits Who’ve Used Marijuana ‘Perform No Worse’ Than Other Soldiers, Military-Funded Report Finds (Marijuana Moment)

Magic Mushrooms

• World-first trial of psilocybin therapy for anxiety disorders to begin in Australia (Happy Mag)

• Psilocybin-assisted psychotherapy might help to reduce attachment anxiety (PsyPost)

• Microdosing Moms: Psilocybin & Postpartum Depression Relief (Truffle Report)

• COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for PTSD (Psilocybin Alpha)

• Psilocybe subaeruginosa: Australia’s Most Famous Magic Mushroom (DoubleBlind)

• A Case Study on Microdosing and Self-Care (The Third Wave)

• Psyched Wellness Announces That the Amanita Muscaria Mushroom Has Been Successfully Added to the Natural Health Products Ingredients Database (NHPID) of Canada (Psilocybin Alpha)

• The Missing Mushroom: Psychedelic Science and the Future of Psilocybin (Psychedelic Science Review)

• Braxia Scientific Graduates First Cohort of Medical Professionals from Psilocybin-Assisted Therapy Training Program; Ready to Start Health Canada Approved Psilocybin Clinical Trial (Psilocybin Alpha)

• Filament Health Announces FDA Authorization of Clinical Trial with First-Ever Direct Psilocin Administration and First-Ever Psychedelic Botanical Drug Candidates (Psilocybin Alpha)

DMT

• Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT in Neuron Study (Psilocybin Alpha)

• PharmaDrug Advances Psychedelics Program with Analogue DMT Formulations to Treat Eye Diseases (Psilocybin Alpha)

• Understanding A DMT Trip: From The Experience To Potential Side Effects (Healing Maps)

Mescaline

• Mescaline Revelations: Hume, Buddhism, and the Illusory Nature of the Self (Sam Woolfe)

Peyote

• The Compounds in Psychedelic Cacti (Psychedelic Science Review)

Iboga

• Ibogaine and Iboga: Traditional Use, Conservation, and Ethical Considerations (DoubleBlind)

Morning Glory Seeds

• Forgotten Psychedelics: LSA — Also Known as Ololiuqui (Psychedelic Spotlight)

Novel Psychoactive Substances

• atai Life Sciences Announces Supportive Interim Data from First 8-Patient Cohort of Phase 2a Trial for Novel Treatment of Cognitive Impairment Associated with Schizophrenia (Psilocybin Alpha)

Ketamine

• Ketamine rapidly improves cognitive function, making those in suicidal crisis less likely to harm themselves (Medical Xpress)

• Kernel’s Brain-Imaging Helmet Approved For Clinical Trial On Patients Using Ketamine (Forbes)

• Klarisana's Newest Ketamine Study Shows IM Ketamine Therapy Comparable to IV Administration (PR Newswire)

• Study: Mixing CBD With Ketamine Might Be Great For Depression (Forbes)

• Ketamine Users Can Ensure Safety with DanceSafe’s New Testing Kit (Lucid News)

• Parents Are Very Open to Ketamine Therapy for Kids, Study Finds (Psychedelic Spotlight)

DXM

• ‘Robotripping’: Perth teens creating cough syrup cocktails as they chase a cheap high (The Age)

Miscellaneous

• Detroit Voters Decriminalize Psychedelics, Joining Ann Arbor (DoubleBlind)

• FDA Approves First Clinical Trial Using Naturally Sourced Psychedelics (Psychedelic Spotlight)

• The False Promise of Psychedelic Utopia (VICE)

• Classic Psychedelics Aren’t Addictive (Discover Magazine)

• Psychedelic Therapy Is Hyped, But It’s Not Risk-Free: How Therapy Abuse Can Retraumatize Clients (Forbes)

• New Orleans shoeshine man wins legal battle over $30,000 seized by DEA agents (NBC News)

• Washington D.C.’s 1st Year of Psychedelic Decrim (Truffle Report)

• Statewide Psychedelic Decriminalization Efforts Are Growing Across the Nation (Lucid News)

• PharmaTher Provides Research Update on Microneedle Patch Delivery Technologies for Psychedelics (Yahoo!)

• Wonderland: Miami Takes Shape as the Largest Psychedelic Medicine Business Event (High Times)

• Oregon’s Drug Decriminalization Has Raised Over $300 Million for Treatment and Services (Filter)

• ‘I’ve experienced states of consciousness beyond this life’: The people turning to psychedelics on their deathbeds (The Independent)

• How the Psychedelic Community Should Respond to Sexual Abuse (Lucid News)

• Psychedelic Research Beyond Depression & Trauma Part II (Truffle Report)

• Science Has Shown Me the Way Ahead with Psychedelics (Chacruna)

• We must address and deconstruct the stigma of psychedelics (The Michigan Daily)

• How Psychedelics Help with Parenting (Reality Sandwich)

Think Wilder is reader-supported. If you enjoyed this week’s update, please consider helping out by becoming a patron, making a one-time donation, or sharing this post with a friend. Thank you for your support.

Disclaimer: "This Week in Psychedelics" does not censor or analyze the news links presented here. The purpose of this column is solely to catalog how psychedelics are presented by the mass media, which includes everything from the latest scientific research to misinformation.

This Week in Psychedelics 11.5.21 Will Be Delayed

Just a heads up—this week’s psychedelic news link roundup will be delayed. It should come out sometime this weekend.

This Week in Psychedelics - 10.29.21

Cannabis

• With export restrictions eased, Colombia's medical cannabis business is poised for liftoff (CNN)

• Federal Survey Identifies Marked Decline in Youth Marijuana Use (NORML)

• Why did Texas ban Delta-8? (Popular Science)

• Cannabis products may help treat symptoms of depression, improve sleep, and increase quality of life, study suggests (PsyPost)

• California Destroys 1M Plants in Marijuana Eradication Campaign (High Times)

• State Attorneys General Warn About Marijuana-Infused Candy And Snacks Ahead Of Halloween (Marijuana Moment)

• The Myth of Cannabis-Infused Halloween Candy—Debunked (High Times)

• Cannabis is one industry that's actually coming out of Covid even stronger (CNN)

• South Dakota Lawmakers Approve Marijuana Legalization Bill As Activists Pursue 2022 Ballot Initiative (Marijuana Moment)

• New York: Officials Moving to Clear Over 400,000 Past Marijuana Convictions (NORML)

• Montana Supreme Court Unanimously Overturns a Pot Conviction, Saying Cops Stopped the Defendant for No Good Reason (Reason)

• Analysis: ‘Government-Grade’ Marijuana More Closely Resembles Hemp, Has Little in Common with Commercially Available Cannabis (NORML)

• Florida judge rules online marijuana ordering sites may resume business (Marijuana Business Daily)

• Louisiana plans to regulate, not ban, delta-8 THC (Marijuana Business Daily)

• Former Arkansas Lawmaker Launches Campaign To Put Marijuana Legalization On The 2022 Ballot (Marijuana Moment)

• Maryland: Most Residents Want to Legalize Marijuana for Adult Use (NORML)

LSD

• Ex-Denver Cop Who Broke Teen's Face for Dancing on LSD to Cost City $1.2 Million (Westword)

Magic Mushrooms

• Study Finds Psilocybin Improves MDD in Patients With Cancer (Psychiatric Times)

• Latest psilocybin patent highlights the swirling battle over psychedelics intellectual property (STAT)

• Italian Activists Turn In More Than Half A Million Signatures For Marijuana And Psilocybin Referendum (Marijuana Moment)

• Dr. Bronner’s Funds Psilocybin Legalization Effort in Connecticut (High Times)

• More Evidence of the Chemical Compound Variability in Magic Mushrooms (Psychedelic Science Review)

• MYND Life Sciences Signs Agreement to Acquire Rights for the Use of Psychedelics to Treat Alzheimer’s Disease and other Dementias (Psilocybin Alpha)

• Nova Mentis Earns Psilocybin Orphan Drug Designation in Europe for Fragile X Syndrome (PR Newswire)

MDMA

• No One Is Wasting Their Ecstasy on Your Kids' Halloween Candy (Reason)

• MindMed Announces R(-)-MDMA Program to target Social Anxiety Associated with Autism Spectrum Disorder (Psilocybin Alpha)

Ayahuasca

• Des Moines church fights IRS over ‘religious’ use of hallucinogenic drug (Iowa Capital Dispatch)

5-MeO-DMT

• Beckley Psytech Announces First Cohort Dosed in Phase 1 Clinical Trial Assessing Safety and Tolerability of Intranasal 5-MeO-DMT (Psilocybin Alpha)

Novel Psychoactive Substances

• Mydecine Reports Successful Synthesis of Novel Tryptamine Improving the Pharmaceutical Properties of Psilocin (Psilocybin Alpha)

• Silo Pharma Enters into Sponsored Research Agreement with Columbia University to Develop Psychedelic Therapeutics for Alzheimer’s Disease (Psilocybin Alpha)

• Awakn Life Sciences Identifies New Chemical Series Via Its Drug Discovery Program (Awakn Life Sciences)

• Marvel Biosciences Announces New Program to Develop Novel Orally Dosed Non-Hallucinogenic Neuroplastic Promoting Compounds (Yahoo! Finance)

Synthetic Cannabinoids

• The Dangers of 'Spice' and Other Synthetic Cannabinoids (Discover Magazine)

Ketamine

• European Patent Grant Strengthens Small Pharma’s Ketamine-Based Patent Portfolio for the Treatment of Depressive Disorders (Psilocybin Alpha)

• Cocaine, ketamine use on the rise: survey (PerthNow)

• Cybin Announces FDA Investigational New Drug Authorization of Cybin’s Sponsored Feasibility Study Using Kernel Flow Technology (Psilocybin Alpha)

• MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol for Alcohol Use Disorder into Clinics Across United States and Canada through iSTRYM, MINDCURE’s Digital Therapeutics Platform (Psilocybin Alpha)

Miscellaneous

• Canadian entrepreneur gifts $5 million to help create psychedelic research centre for mental health (CTV News)

• Where the Psychedelic Revolution Is Headed, According to the Guy Who (Arguably) Started It (GQ)

• Psychedelics Group Issues First Round Of Grants For Community-Based Entheogenic Education In DC (Marijuana Moment)

• Addressing Abuse in Psychedelic Spaces (Psychedelics Today)

• North America Continues Leading The Way In Psychedelic Wellness (PR Newswire)

• Psychedelic Patents Should Be Limited, Harvard Law Experts Say (Psychedelic Spotlight)

• Could Psychedelics Cure Our Post-Pandemic Depression? (Truffle Report)

• How Gender Affects the Way We Use Drugs (TalkingDrugs)

• DC Voters Strongly Support Drug Decriminalization, Poll Finds As Activists Launch Campaign (Marijuana Moment)

• MAPS Canada’s Data Breach Foreshadows Corporadelic Future (Psymposia)

• Wavepaths: The Neuroscientist-Founded Company Producing Music For—And As—Psychedelic Therapy (Forbes)

• Novamind Brings Contract Research To Psychedelic Medicine (Lucid News)

• Psychedelic Research Beyond Depression & Trauma (Truffle Report)

Think Wilder is reader-supported. If you enjoyed this week’s update, please consider helping out by becoming a patron, making a one-time donation, or sharing this post with a friend. Thank you for your support.

Disclaimer: "This Week in Psychedelics" does not censor or analyze the news links presented here. The purpose of this column is solely to catalog how psychedelics are presented by the mass media, which includes everything from the latest scientific research to misinformation.